Research Library

Products containing hemp extracts high in CBD are gaining mainstream popularity, acceptance and federal legality. In this article, Lisa Pittman, nonresident fellow in drug policy, focuses on litigation issues particular to hemp.

President Trump's plan to designate Mexican drugs cartels as foreign terrorist organizations is a mistake, says nonresident fellow Gary Hale. Read why in the Baker Institute Blog.

Fellow Katharine Neill Harris considers the validity of risk assessment tools, which estimate the likelihood that an individual who has been charged with or convicted of a crime will commit a future offense. Baker Institute Blog: https://bit.ly/2Cwl6jc

Body-worn cameras (BWCs) are becoming a permanent fixture of modern policing, and their effects are likely to be much more nuanced than originally predicted.

Despite the wealth of evidence attesting to the efficacy of medication-assisted treatment for opioid addiction, the majority of Americans who need it can't get it — including in Harris County, Texas’ largest county. Baker Institute Blog: https://bit.ly/31D9qGV

The authors examine new legislation in Tunisia aimed at increasing protections for women, such as repealing the country’s “marry-your-rapist” law as well as criminalizing marital rape and domestic violence.

The Commission on Combatting Drug Addiction and the Opioid Crisis appointed by President Trump released its report on Monday, July 31. Drug policy fellow Katharine Neill Harris assesses the commission's recommendations in the Baker Institute Blog.

Drug policy fellow Katharine A. Neill explains why establishing heroin-assisted treatment programs, which provide severely addicted individuals with controlled access to pharmaceutical-grade heroin, could make a significant dent in the number of U.S. deaths from opioid use in this post for the Baker Institute Blog.

The Texas House of Representatives is considering House Bill 3256, which would legalize syringe exchange programs (SEPs) as a means of reducing the transmission of infectious and communicable diseases among people who inject drugs. On April 25, William Martin, director of the Drug Policy Program, appeared before the Texas House Committee on Public Health to testify in support of HB 3256. Martin also authored an op-ed in TribTalk supporting the establishment of SEPs.